CoverageForm 410-K10-Q8-K13D13G13F

DGX · Quest Diagnostics Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · DGX

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue$2.90B-$2.82B$2.76B$2.65B-$2.49B$2.40B$2.37B-
Cost of Revenue$1.95B-$1.87B$1.82B$1.79B-$1.68B$1.59B$1.59B-
Gross Profit$942.00M-$949.00M$943.00M$863.00M-$811.00M$804.00M$771.00M-
R&D----------
SG&A$504.00M-$501.00M$486.00M$476.00M-$448.00M$416.00M$440.00M-
Total Operating Expenses$2.50B-$2.43B$2.32B$2.31B-$2.16B$2.04B$2.07B-
D&A$147.00M-$142.00M$143.00M$140.00M-$125.00M$117.00M$116.00M-
Operating Income$399.00M-$386.00M$438.00M$346.00M-$330.00M$355.00M$300.00M-
Interest Expense-------$47.00M$49.00M-
Income Tax$74.00M-$77.00M$97.00M$59.00M-$65.00M$74.00M$66.00M-
Net Income$252.00M-$245.00M$282.00M$220.00M-$226.00M$229.00M$194.00M-
EPS - Basic$2.27-$2.18$2.51$1.97-$2.01$2.05$1.74-
EPS - Diluted$2.24-$2.16$2.47$1.94-$1.99$2.03$1.72-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$393.00M$420.00M$432.00M$319.00M$188.00M$549.00M$764.00M$271.00M$474.00M$686.00M
Accounts Receivable$1.59B$1.41B$1.46B$1.42B$1.40B$1.30B$1.38B$1.32B$1.32B$1.21B
Inventory$225.00M$189.00M$186.00M$187.00M$189.00M$188.00M$184.00M$182.00M$181.00M$190.00M
Accounts Payable-$307.00M---$287.00M---$378.00M
Current Assets$2.57B$2.38B$2.41B$2.20B$2.08B$2.39B$2.62B$2.02B$2.23B$2.37B
Total Assets$16.67B$16.23B$16.20B$15.97B$15.80B$16.15B$16.09B$13.88B$13.95B$14.02B
Current Liabilities$2.18B$2.28B$2.13B$2.02B$1.44B$2.17B$2.09B$2.01B$2.30B$1.81B
Long-term Debt-$5.17B---$5.62B$5.65B--$4.41B
Total Liabilities----------
Stockholders' Equity$7.37B$7.17B$7.26B$7.23B$6.93B$6.78B$6.81B$6.62B$6.43B$6.31B
Retained Earnings$10.15B$9.99B$9.84B$9.68B$9.49B$9.36B$9.22B$9.08B$8.94B$8.82B

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow$278.00M---$314.00M---$154.00M-
Investing Cash Flow($152.00M)---($115.00M)---($213.00M)-
Financing Cash Flow($152.00M)---($561.00M)---($153.00M)-
CapEx$114.00M---$117.00M---$104.00M-
Free Cash Flow$164.00M---$197.00M---$50.00M-

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin32.5%-33.7%34.2%32.5%-32.6%33.5%32.6%-
Operating margin13.8%-13.7%15.9%13.0%-13.3%14.8%12.7%-
EBITDA margin18.9%-18.8%21.0%18.3%-18.3%19.7%17.6%-
Net margin8.7%-8.7%10.2%8.3%-9.1%9.6%8.2%-
Free cash flow margin5.7%---7.4%---2.1%-
FCF / Net income0.65---0.90---0.26-
R&D / Revenue----------
SG&A / Revenue17.4%-17.8%17.6%17.9%-18.0%17.4%18.6%-
Effective tax rate22.7%-23.9%25.6%21.1%-22.3%24.4%25.4%-
Return on assets1.5%-1.5%1.8%1.4%-1.4%1.6%1.4%-
Return on equity3.4%-3.4%3.9%3.2%-3.3%3.5%3.0%-
Return on invested capital------2.1%---
Liquidity
Current ratio1.181.041.131.091.441.101.251.000.971.31
Quick ratio1.080.961.040.991.311.021.170.910.891.20
Cash ratio0.180.180.200.160.130.250.370.130.210.38
Leverage
Debt / Equity-0.72---0.830.83--0.70
Debt / Assets-0.32---0.350.35--0.31
Debt / EBITDA------12.41---
Interest coverage-------7.6x6.1x-
Equity multiplier2.262.262.232.212.282.382.362.102.172.22
Liabilities / Assets----------
Efficiency
Asset turnover0.17-0.170.170.17-0.150.170.17-
Inventory turnover8.68-10.049.729.47-9.118.758.81-
Days sales outstanding200d-189d188d193d-202d201d204d-
Days inventory outstanding42d-36d38d39d-40d42d41d-
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E87.5x-88.2x72.7x87.2x-78.0x67.4x77.4x-
P / B3.0x-3.0x2.8x2.8x-2.6x2.3x2.3x-
P / S7.6x-7.6x7.4x7.2x-7.1x6.4x6.3x-
EV / EBITDA39.5x-40.0x34.4x39.0x-49.3x31.9x34.7x-
Growth
Revenue growth (YoY)9.2%-13.2%15.2%12.1%-8.4%2.5%1.5%-
Revenue CAGR (3y)7.5%-4.2%4.0%0.5%--3.6%-2.0%-4.5%-
Revenue CAGR (5y)1.3%-0.2%8.6%7.8%-5.7%4.5%4.6%-
Gross profit growth (YoY)9.2%-17.0%17.3%11.9%-7.6%1.5%0.0%-
Operating income growth (YoY)15.3%-17.0%23.4%15.3%--3.5%2.0%-1.6%-
Net income growth (YoY)14.5%-8.4%23.1%13.4%-0.4%-2.6%-4.0%-
EPS growth (YoY)15.5%-8.5%21.7%12.8%-1.5%-1.0%-3.4%-
EPS CAGR (3y)8.0%--0.2%8.0%-12.7%--20.9%-25.8%-20.8%-
EPS CAGR (5y)-8.3%--12.2%12.7%21.6%-5.0%4.1%7.5%-
FCF growth (YoY)-16.8%---294.0%-----
FCF CAGR (5y)-24.0%---3.7%----26.2%-
Book value growth (YoY)6.3%5.8%6.6%9.2%7.7%7.5%6.0%5.9%6.3%7.0%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$11.04B total
Diagnostic Information Services Business$10.79B · 97.7%
All Other Segments$250.00M · 2.3%

Peer comparison

Same SIC group: Services-Medical Laboratories

CompanyRevenue (last FY)Net marginROE
NTRA$2.31B-9.0%-12.2%
GH$982.02M-42.4%419.2%
LH$13.95B6.3%10.2%
CSTL$344.23M-7.0%-5.1%
BDSX$88.50M-39.8%1430.6%

Comparing QUEST DIAGNOSTICS INC against the 5 most active filers in the same SIC group.

Dividends

$3.26/share trailing 12 months · +6.9% YoY

Ex-datePer share
Apr 6, 2026$0.8600
Jan 13, 2026$0.8000
Oct 3, 2025$0.8000
Jul 7, 2025$0.8000
Apr 7, 2025$0.8000
Jan 14, 2025$0.7500
Oct 4, 2024$0.7500
Jul 8, 2024$0.7500
Apr 5, 2024$0.7500
Jan 16, 2024$0.7100
Oct 5, 2023$0.7100
Jul 10, 2023$0.7100
Apr 6, 2023$0.7100
Jan 17, 2023$0.6600
Oct 3, 2022$0.6600
Jul 5, 2022$0.6600
Apr 5, 2022$0.6600
Jan 18, 2022$0.6200
Oct 4, 2021$0.6200
Jul 6, 2021$0.6200
Apr 6, 2021$0.6200
Jan 19, 2021$0.5600
Oct 5, 2020$0.5600
Jul 7, 2020$0.5600